ASX: IPD

9 March 2015

**ASX ANNOUNCEMENT**

## US Nationally Recognised Hospital joins L-Dex® Trial

## HIGHLIGHTS

- Mayo Clinic, a world-leading hospital, has joined the L-Dex post-approval trial[1]
- Principal Investigator is Mayo Clinic associate professor of surgery Sarah McLaughlin, MD, FACS

Brisbane, Australia – ImpediMed Limited (ASX: IPD) ("the Company") is pleased to announce that Mayo Clinic in Jacksonville, Florida has joined an illustrious list of National Cancer Institute (NCI) designated comprehensive cancer centres for the L-Dex international, post-approval clinical trial.

Dr Sarah McLaughlin, who has been named principal investigator for this trial site joins a group of renowned researchers including Prof Sheila Ridner, Dr Frank Vicini, Prof John Boyages, Dr Sarah DeSnyder and Louise Koelmeyer. The researchers hail from world recognised academic centres of Vanderbilt University, Macquarie University and MD Anderson Cancer Center.

"The Mayo Clinic Cancer Center in Florida joins a list of prestigious sites involved in the post-approval clinical trial of L-Dex. We are very pleased to have Dr McLaughlin added to this list of eminent researchers," said Richard Carreon, CEO of ImpediMed.

Details of the clinical trial can be found at the US National Institutes of Health website:
http://clinicaltrials.gov/ct2/show/NCT02167659?term=impedimed&rank=6

[1] Previous announcements at ASX on 30th October 2013, 26th June 2014, 23rd July 2014 and 5th March 2015

**Richard Carreon**
**CEO**

**ENDS**

**For further information contact:**
**Richard Carreon, ImpediMed CEO**
**Morten Vigeland, ImpediMed CFO**
**T: +1 (760) 585-2100**

**Kyahn Williamson, Buchan**
**Investor and Media Relations**
**T: +61 3 9866 4722**
**E: kwilliamson@buchanwe.com.au**

**About ImpediMed**
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au